Predicting and Preventing Immune Checkpoint Inhibitor Toxicity: Targeting Cytokines

被引：74
作者：
Kang, Jee Hye [1 ,2 ]
Bluestone, Jeffrey A. [1 ,2 ,3 ]
Young, Arabella [1 ,2 ,4 ]
机构：
[1] Univ Calif San Francisco, Sean N Parker Autoimmune Res Lab, San Francisco, CA 94143 USA
[2] Univ Calif San Francisco, Ctr Diabet, San Francisco, CA 94143 USA
[3] Sonoma Biotherapeut, San Francisco, CA USA
[4] QIMR Berghofer Med Res Inst, Herston, Qld, Australia
来源：
TRENDS IN IMMUNOLOGY | 2021年 / 42卷 / 04期
基金：
美国国家卫生研究院; 英国医学研究理事会;
关键词：
ADVERSE EVENTS; 1ST-LINE TREATMENT; ADVANCED MELANOMA; CLINICAL IMPACT; INDUCED COLITIS; TH17; CELLS; ANTI-TNF; CANCER; IPILIMUMAB; NIVOLUMAB;
D O I：
10.1016/j.it.2021.02.006
中图分类号：
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号：
100102 ;
摘要：
Cancer immunotherapies can successfully activate immune responses towards certain tumors. However, this can also result in the development of treatmentinduced immune-related adverse events (irAEs) in multiple tissues. Growing evidence suggests that cytokine production in response to these therapeutics potentiates the development of irAEs and may have predictive value as biomarkers for irAE occurrence. In addition, therapeutic agents that inhibit cytokine activity can limit the severity of irAEs, and their use is being tested in the clinical setting. This review provides an in-depth analysis of strategies to uncouple the cytokine response, that precipitates irAEs following cancer immunotherapies, from the benefit gained in promoting antitumor immunity.
引用
收藏
页码：293 / 311
页数：19
相关论文
共 121 条
  • [1] Early introduction of selective immunosuppressive therapy associated with favorable clinical outcomes in patients with immune checkpoint inhibitor-induced colitis
    Abu-Sbeih, Hamzah
    Ali, Faisal S.
    Wang, Xuemei
    Mallepally, Niharika
    Chen, Ellie
    Altan, Mehmet
    Bresalier, Robert S.
    Charabaty, Aline
    Dadu, Ramona
    Jazaeri, Amir
    Lashner, Bret
    Wang, Yinghong
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7
  • [2] Phase II Trial of IL-12 Plasmid Transfection and PD-1 Blockade in Immunologically Quiescent Melanoma
    Algazi, Alain P.
    Twitty, Christopher G.
    Tsai, Katy K.
    Le, Mai
    Pierce, Robert
    Browning, Erica
    Hermiz, Reneta
    Canton, David A.
    Bannavong, Donna
    Oglesby, Arielle
    Francisco, Murray
    Fong, Lawrence
    Pittet, Mikael J.
    Arlauckas, Sean P.
    Garris, Christopher
    Levine, Lauren P.
    Bifulco, Carlos
    Ballesteros-Merino, Carmen
    Bhatia, Shailender
    Gargosky, Sharron
    Andtbacka, Robert H. I.
    Fox, Bernard A.
    Rosenblum, Michael D.
    Daud, Adil I.
    [J]. CLINICAL CANCER RESEARCH, 2020, 26 (12) : 2827 - 2837
  • [3] Infliximab for IPILIMUMAB-Related Colitis-Letter
    Arriola, Edurne
    Wheater, Matthew
    Karydis, Ioannis
    Thomas, Gareth
    Ottensmeier, Christian
    [J]. CLINICAL CANCER RESEARCH, 2015, 21 (24) : 5642 - 5643
  • [4] Concurrent therapy with immune checkpoint inhibitors and TNFα blockade in patients with gastrointestinal immune-related adverse events
    Badran, Yousef R.
    Cohen, Justine, V
    Brastianos, Priscilla K.
    Parikh, Aparna R.
    Hong, Theodore S.
    Dougan, Michael
    [J]. JOURNAL FOR IMMUNOTHERAPY OF CANCER, 2019, 7 (01):
  • [5] Enterocolitis in patients with cancer after antibody blockade of cytotoxic T-lymphocyte-associated antigen 4
    Beck, Kimberly E.
    Blansfield, Joseph A.
    Tran, Khoi Q.
    Feldman, Andrew L.
    Hughes, Marybeth S.
    Royal, Richard E.
    Kammula, Udai S.
    Topalian, Suzanne L.
    Sherry, Richard M.
    Kleiner, David
    Quezado, Martha
    Lowy, Israel
    Yellin, Michael
    Rosenberg, Steven A.
    Yang, James C.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (15) : 2283 - 2289
  • [6] Association of Checkpoint Inhibitor-Induced Toxic Effects With Shared Cancer and Tissue Antigens in Non-Small Cell Lung Cancer
    Berner, Fiamma
    Bomze, David
    Diem, Stefan
    Ali, Omar Hasan
    Faessler, Mirjam
    Ring, Sandra
    Niederer, Rebekka
    Ackermann, Christoph J.
    Baumgaertner, Petra
    Pikor, Natalia
    Cruz, Cristina Gil
    van de Veen, Willem
    Akdis, Muebeccel
    Nikolaev, Sergey
    Laeubli, Heinz
    Zippelius, Alfred
    Hartmann, Fabienne
    Cheng, Hung-Wei
    Hoenger, Gideon
    Recher, Mike
    Goldman, Jonathan
    Cozzi, Antonio
    Fruek, Martin
    Neefjes, Jacques
    Driessen, Christoph
    Ludewig, Burkhard
    Hegazy, Ahmed N.
    Jochum, Wolfram
    Speiser, Daniel E.
    Flatz, Lukas
    [J]. JAMA ONCOLOGY, 2019, 5 (07) : 1043 - 1047
  • [7] TNFα blockade overcomes resistance to anti-PD-1 in experimental melanoma
    Bertrand, Florie
    Montfort, Anne
    Marcheteau, Elie
    Imbert, Caroline
    Gilhodes, Julia
    Filleron, Thomas
    Rochaix, Philippe
    Andrieu-Abadie, Nathalie
    Levade, Thierry
    Meyer, Nicolas
    Colacios, Celine
    Segui, Bruno
    [J]. NATURE COMMUNICATIONS, 2017, 8
  • [8] Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study
    Biran, Noa
    Ip, Andrew
    Ahn, Jaeil
    Go, Ronaldo C.
    Wang, Shuqi
    Mathura, Shivam
    Sinclaire, Brittany A.
    Bednarz, Urszula
    Marafelias, Michael
    Hansen, Eric
    Siegel, David S.
    Goy, Andre H.
    Pecora, Andrew L.
    Sawczuk, Ihor S.
    Koniaris, Lauren S.
    Simwenyi, Micky
    Varga, Daniel W.
    Tank, Lisa K.
    Stein, Aaron A.
    Allusson, Valerie
    Lin, George S.
    Oser, William F.
    Tuma, Roman A.
    Reichman, Joseph
    Brusco, Louis, Jr.
    Carpenter, Kim L.
    Costanzo, Eric J.
    Vivona, Vincent
    Goldberg, Stuart L.
    [J]. LANCET RHEUMATOLOGY, 2020, 2 (10) : E603 - E612
  • [9] Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: American Society of Clinical Oncology Clinical Practice Guideline
    Brahmer, Julie R.
    Lacchetti, Christina
    Schneider, Bryan J.
    Atkins, Michael B.
    Brassil, Kelly J.
    Caterino, Jeffrey M.
    Chau, Ian
    Ernstoff, Marc S.
    Gardner, Jennifer M.
    Ginex, Pamela
    Hallmeyer, Sigrun
    Chakrabarty, Jennifer Holter
    Leighl, Natasha B.
    Mammen, Jennifer S.
    McDermott, David F.
    Naing, Aung
    Nastoupil, Loretta J.
    Phillips, Tanyanika
    Porter, Laura D.
    Puzanov, Igor
    Reichner, Cristina A.
    Santomasso, Bianca D.
    Seigel, Carole
    Spira, Alexander
    Suarez-Almazor, Maria E.
    Wang, Yinghong
    Weber, Jeffrey S.
    Wolchok, Jedd D.
    Thompson, John A.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (17) : 1714 - +
  • [10] Corticosteroids, But Not TNF Antagonists, Are Associated With Adverse COVID-19 Outcomes in Patients With Inflammatory Bowel Diseases: Results From an International Registry
    Brenner, Erica J.
    Ungaro, Ryan C.
    Gearry, Richard B.
    Kaplan, Gilaad G.
    Kissous-Hunt, Michele
    Lewis, James D.
    Ng, Siew C.
    Rahier, Jean-Francois
    Reinisch, Walter
    Ruemmele, Frank M.
    Steinwurz, Flavio
    Underwood, Fox E.
    Zhang, Xian
    Colombel, Jean-Frederic
    Kappelman, Michael D.
    [J]. GASTROENTEROLOGY, 2020, 159 (02) : 481 - +
12345678910